The HGF and MET genes are collectively altered (amplified, overexpressed and/or mutated) in published and provisional GBM datasets compiled by The Cancer Genome Atlas (TCGA) Research Network in 7.5% of 206 cases [13] and 18% of 291 [14] and 528 cases [15]; 2% of the latter 819 cases show concomitant overexpression or amplification of both genes [14,15]. The gene discussed is MET; the disease is glioblastoma.